摘要
目的探究细胞因子诱导的杀伤细胞(CIK)联合顺铂化疗治疗卵巢癌的临床疗效。方法将2012年1月至2015年1月于徐州矿务集团总医院妇产科就诊的80例卵巢癌患者按抽签法随机分为试验组和对照组,各40例。两组均采用紫杉醇+顺铂方案化疗方案作为基础治疗,按紫杉醇注射液135 mg/m^2、注射用顺铂75 mg/m^2静脉注射,治疗周期为3周,共2个周期。试验组在基础化疗的基础上采用CIK治疗。比较两组患者的临床疗效,人附睾蛋白4(HE4)、血管内皮生长因子(VEGF)水平变化及不良反应发生情况。结果试验组总疾病控制率高于对照组[90.0%(36/40)比72.5%(29/40)](P<0.05)。治疗后,试验组患者HE4和VEGF水平低于对照组[(71±13)pmol/L比(134±18)pmol/L,(213±45)ng/L比(350±65)ng/L](P<0.01)。试验组患者白细胞降低和血红蛋白降低发生率低于对照组[42.5%(17/40)比72.5%(29/40),37.5%(15/40)比67.5%(27/40)](P<0.05)。结论 CIK联合顺铂方案化疗治疗卵巢癌患者的临床效果较好,不良反应发生率低。
Objective To evaluate the efficacy and toxicity of cytokine-induced killer cells （CIK） with cisplatin in the treatment of patients with ovarian tumor. Methods A total of 80 patients with ovarian tumor treated in the Second Affiliated Hospital of Xuzhou Medical College during Jan. 2012 and Jan. 2015 were randomly assigned to two groups according to the draw method, the trial group（ n = 40 ） and the control group（ n = 40 ）. Both groups adopted same basic treatment of taxol 135 mg/m^2 , cisplatin 75 mg/m^2 ,3 weeks as a cycle, for 2 cycles. And the trial group received CIK treatment on the basis of the basic chemotherapy. The level of human epididymis protein 4 （HE4） and vascular endothe-lial growth factor（VEGF） , curative effects and adverse effects of the two groups were compared. Results Total disease control rate of the trial group was higher than that of the control group[ 90.0% （36/40） vs 72.5 % （29/40） ] （ P 〈 0.05 ）. After treatment, the levels of HE4 and VEGF in the trial group were lower than those in the control group （71±13） pmol/L vs （134 ± 18） pmoL/L, （213±45） ng/L vs （350 ±65） ng/L] （P 〈0.01）. The incidence of white blood cell and hemoglobin decrease in the trial group were lower than that of the control group[ 42.5% （ 17/40 ） vs72.5%（29/40）,37.5%（15/40） vs 67.5% （27/40）] （P〈0.05）. Conclusion The efficacy of CIK treat- ment combined with cisplatin in the treatment of patients with malignant ovarian tumor is better with lower adverse reaction incidence.
作者
郝晓园
王新梅
王灵芝
HAO Xiaoyuan WANG Xinmei WANG Lingzhi(Department of Obstetrics and Gynecology, General Hospital of Xuzhou Mining Group ,Xuzhou 221002, China Department of Gynecology and Obstetrics, the Affiliated Hospital of Qingdao university, Qingdao 266003, China)
出处
《医学综述》
2017年第8期1652-1655,共4页
Medical Recapitulate
关键词
卵巢癌
杀伤细胞
化疗
顺铂
血管内皮生长因子
人附睾蛋白
Ovarian cancer
Killer cell
Chemotherapy
Cisplatin
Vascular endothelial growth factor
Human epididymis protein
